The stock has a 36-month beta value of 0.46. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VIR is 89.25M, and at present, short sellers hold a 5.32% of that float. On July 26, 2024, the average trading volume of VIR was 1.17M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VIR) stock’s latest price update
Vir Biotechnology Inc (NASDAQ: VIR) has experienced a rise in its stock price by 5.54 compared to its previous closing price of 10.10. However, the company has seen a gain of 4.31% in its stock price over the last five trading days. businesswire.com reported 2024-07-18 that SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may ac.
VIR’s Market Performance
Vir Biotechnology Inc (VIR) has experienced a 4.31% rise in stock performance for the past week, with a 15.62% rise in the past month, and a 32.59% rise in the past quarter. The volatility ratio for the week is 5.44%, and the volatility levels for the past 30 days are at 4.55% for VIR. The simple moving average for the last 20 days is 14.27% for VIR’s stock, with a simple moving average of 10.77% for the last 200 days.
Analysts’ Opinion of VIR
Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR by listing it as a “Neutral.” The predicted price for VIR in the upcoming period, according to JP Morgan is $9 based on the research report published on January 29, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see VIR reach a price target of $14, previously predicting the price at $23. The rating they have provided for VIR stocks is “Neutral” according to the report published on September 08th, 2023.
JP Morgan gave a rating of “Overweight” to VIR, setting the target price at $34 in the report published on March 06th of the previous year.
VIR Trading at 7.86% from the 50-Day Moving Average
After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.30% of loss for the given period.
Volatility was left at 4.55%, however, over the last 30 days, the volatility rate increased by 5.44%, as shares surge +17.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.11% upper at present.
During the last 5 trading sessions, VIR rose by +4.31%, which changed the moving average for the period of 200-days by +20.45% in comparison to the 20-day moving average, which settled at $9.41. In addition, Vir Biotechnology Inc saw 5.96% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIR starting from Ramasastry Saira, who sale 4,000 shares at the price of $10.95 back on Jun 11 ’24. After this action, Ramasastry Saira now owns 14,619 shares of Vir Biotechnology Inc, valued at $43,789 using the latest closing price.
De Backer Marianne, the Chief Executive Officer of Vir Biotechnology Inc, sale 72,995 shares at $9.46 during a trade that took place back on Apr 03 ’24, which means that De Backer Marianne is holding 678,457 shares at $690,365 based on the most recent closing price.
Stock Fundamentals for VIR
Current profitability levels for the company are sitting at:
- -10.14 for the present operating margin
- 0.82 for the gross margin
The net margin for Vir Biotechnology Inc stands at -9.57. The total capital return value is set at -0.34. Equity return is now at value -30.67, with -24.19 for asset returns.
Based on Vir Biotechnology Inc (VIR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.3. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -2391.28.
Currently, EBITDA for the company is -641.55 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 24.8. The receivables turnover for the company is 5.75for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.90.
Conclusion
To sum up, Vir Biotechnology Inc (VIR) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
